StreetAlpha.app
Home › Stocks › ARGX

Argenx SE (ARGX)

Healthcare
$925.70
▼ −1.73%
LAST CLOSE · NOV 20

argenx develops antibody medicines for autoimmune and neuromuscular diseases, with its main product VYVGART. It last closed at $925.70 on Nov 20, down 1.73% on the day.

AI Auto Pilots
Is ARGX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ARGX.

Key Stats

Last 12 months
Results
Net income
$1.3B
+55.1% vs a year ago
Free cash flow
$679.0M
Balance sheet
Cash & equivalents
$3.5B
At Dec 31
Shareholder equity
$7.3B
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$408.3M−$408.3MFY2021FY2022: −$709.6M−$709.6MFY2022FY2023: −$295.1M−$295.1MFY2023FY2024: $833.0M$833.0MFY2024FY2025: $1.3B$1.3BFY2025

From ARGX's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 19). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
EPS and revenue estimates
Year-ago EPS
Same quarter last year
Options-implied move
Move priced in by options
Analyst consensus
Ratings from the last 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ARGX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ARGX

Technical Analysis

ARGX · as of the Nov 20 close · updated each morning
Uptrend

The stock sits between its 20 and 50 day averages. It is 7% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 50). The nearest support is the 100 day average at $925.02, and the nearest resistance the 20 day average at $926.20.

Short trendBullish
Long trendBullish
MomentumImproving
StretchNormal
VolatilityNormal, 2.9%/day
Key levels
$1072.7552 week high+15.9%
$941.20Pivot R1+1.7%
$933.99Swing high (Jun 23)+0.9%
$933.17Pivot+0.8%
$926.2020 day average+0.1%
$925.70Last close
$925.02100 day average−0.1%
$917.8150 day average−0.9%
$917.68Pivot S1−0.9%
$862.82200 day average−6.8%
$845.30Swing low (Jul 23)−8.7%
$661.8552 week low−28.5%
Indicators
RSI (14)49.95Middle of its rangeNeutral
MACD12.65Above its signal lineBullish
Stochastic54.7Middle of its rangeNeutral
ADX (14)18.8No clear trend
Williams %R-54.7Oversold below −80, overbought above −20Neutral
CCI (20)15.4Oversold below −100, overbought above 100Neutral
Rate of change−0.2%Change over 10 sessionsBearish
ATR (14)$26.87Typical daily range, 2.9% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for ARGX

What happened before

See how ARGX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ARGX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ARGX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ARGXHow many large options trades hit ARGX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

ARGX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲313 buying vs 192 selling
  • ●Shares held by funds -0.9%
  • ▲Funds holding +42
  • ▲Superinvestors: 4 added, 0 cut
  • ▼Put/call 0.14 to 0.74
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding555513+8.2%
In funds' top 101413+7.7%
Held by funds–––
New / increased90 / 22381 / 179+20.4%
Reduced / sold out144 / 48164 / 50−10.3%
Put/call ratio0.740.14+427.4%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ARGX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARGX is in one of them and how their past ARGX trades turned out.

ARGX in the AI portfolios
Loading…

ARGX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ARGX in an article yet. Here's the latest on the wider market.

ARGX in the news

ARGX Congress Trades

All congress trades →
Trades, 12 months
4
Buys
4
100%
Sells
0
0%
People
2
Last filed Nov 10
Who traded ARGX · since 2023
Latest 5 filings
$1K – $15KTraded Oct 27, 2026Filed Nov 10, 2026
$1K – $15KTraded Oct 15, 2026Filed Nov 10, 2026
$15K – $50KTraded Oct 14, 2026Filed Nov 10, 2026
$1K – $15KTraded Mar 30, 2026Filed Jul 21, 2026
$1K – $15KTraded Jul 10, 2023Filed Aug 13, 2023
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KOct 27, 2026Nov 10, 202614 d
Gilbert CisnerosD · CABuy$1K – $15KOct 15, 2026Nov 10, 202626 d
Gilbert CisnerosD · CABuy$15K – $50KOct 14, 2026Nov 10, 202627 d
Alan ArmstrongR · OKBuy$1K – $15KMar 30, 2026Jul 21, 2026113 d
Dan GoldmanD · NYSell$1K – $15KJul 10, 2023Aug 13, 202334 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Argenx SE

argenx is a biopharmaceutical company that develops antibody medicines for autoimmune and neuromuscular diseases. Its main product, VYVGART, is approved for several conditions, including generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP). The company sells its medicines to patients and works with healthcare professionals, and it is developing a range of other candidates in clinical trials. It is based in Zwijnaarde.

Headquarters
Zwijnaarde